CHIOME BIOSCIENCE
Chiome Bioscience was established in 2005 to commercialize the innovative ADLib® antibody generation technology invented at RIKEN. Since that time the Company has worked on research and development for this system, as well as initiatives for technology licensing. It focused mainly on joint research and contract research with the research arms of pharmaceutical companies and academia. Meanwhile, in 2011 the Company was listed on the Mothers market of the Tokyo Stock Exchange, and in 2015 it merg... ed with LivTech which focused on drug discovery and development of therapeutic antibody for oncology, thus adding drug discovery function. In 2017 the Company went through reorganization of the management team, switching its strategy from platform development to drug discovery and development. At the same time it started setting up the clinical function which enables us to run a clinical study aiming of significant increase in corporate value.
CHIOME BIOSCIENCE
Industry:
Biotechnology Health Care
Founded:
2005-02-08
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.chiome.co.jp
Total Employee:
11+
Status:
Active
Contact:
+81-3-6383-3561
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Apache
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
M&B Sciences
M&B Sciences is a fast-growing African-American-owned, technology-driven clinical research organization.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-03-16 | LivTech | LivTech acquired by Chiome Bioscience | N/A |
Investors List
Fast Track Initiative, Inc.
Fast Track Initiative, Inc. investment in Funding Round - Chiome Bioscience
Official Site Inspections
http://www.chiome.co.jp Semrush global rank: 2.49 M Semrush visits lastest month: 7.09 K
- Host name: chiome.co.jp
- IP address: 202.229.135.157
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Chiome Bioscience"
IR情報│業績・財務情報│株式会社カイオム・バイオサ …
An introduction to Chiome Bioscience’s antibody technology platform including our proprietary ADLib ® system. Pipeline パイプライン 当社が開発するパイプラインの進捗状況や詳細をご確認いただけます。See details»
Overview 会社概要 - 株式会社カイオム・バイオサイエ …
会社名 Name 株式会社 カイオム・バイオサイエンス Chiome Bioscience Inc.; 英語表記 Chiome Bioscience Inc. 事業内容 Business 独自の創薬基盤技術であるADLib®システムを核とした抗体医薬品の創薬事業および創薬支援事業等 …See details»
Chiome Bioscience - Crunchbase Company Profile
Chiome Bioscience was established in 2005 to commercialize the innovative ADLib® antibody generation technology invented at RIKEN. Since that time …See details»
Chiome Bioscience Company Profile - Office Locations ... - Craft
Oct 11, 2024 Chiome Bioscience has 3 employees across 2 locations and ¥682.46 m in annual revenue in FY 2023. See insights on Chiome Bioscience including office locations, …See details»
CHIOME BIOSCIENCE Company Profile & Introduction - moomoo
Feb 8, 2005 Introduction of CHIOME BIOSCIENCE, including company profile, stock information, contact number, and company business introduction. ... JP Stock Market Detailed …See details»
CBA-1535の第I相臨床試験 - niph.go.jp
Dec 28, 2024 組織名 / Organization: 部署名 / Division: Chiome Bioscience Inc. 住所 / Address: Sumitomo-Fudosan Nishi-shinjuku bldg. No.6, 3-12-1 Honmachi, Shibuya-ku, Tokyo Tokyo …See details»
Full List of Biotech Companies in Japan (2025)
Mar 1, 2025 BioPhenolics Inc. 5-5-5 Tokodai, Tsukuba, 300-2635 Ibaraki, Japan Email: [email protected] https://www.bio-phenolics.com bitBiome, Inc. HQ: 415 Research Innovation Center, …See details»
Business alliance agreement for co-development of biosimilars
Jun 18, 2024 President & CEO Shinya Kurebayashi and Chiome Bioscience Inc. (hereinafter “Chiome”), headquartered in Tokyo, Japan and led by President & CEO Shigeru Kobayashi …See details»
IRライブラリ│株式会社カイオム・バイオサイエンス
An introduction to Chiome Bioscience’s antibody technology platform including our proprietary ADLib ® system. Pipeline パイプライン 当社が開発するパイプラインの進捗状況や詳細をご確認いただけます。See details»
カイオム・バイオサイエンス（4583） 早期の黒字化、収益拡大 …
Sep 7, 2023 この他、Chiome’s mAb Discovery Engine（技術ポートフォリオ）充足および技術改良のための共同研究を実施中である。また、他社技術も取り込み、同社のコアコンピタン …See details»
出資先「ニッセイ・キャピタル_カイオム・バイオサイエン …
「ADLib®システム」をはじめとする複数の抗体作製技術を展開する企業。2011年12月には東京証券取引所マザーズに新規上場を ...See details»
Chiome Bioscience - omega-inv.com
Chiome Bioscience TYO: 4583 Albeit being a high-risk investment, Chiome shares may well offer interesting upside over the long term. Research and development is progressing steadily, and …See details»
Company: Chiome Bioscience Inc. Representative: Shigeru …
Chiome Bioscience develop PCDC as one of our therapeutic pipelines and have completed patent applications for this antibody. We are currently actively working to make a license agreement …See details»
株式会社カイオム・バイオサイエンスの採用・求人情報-engage
株式会社カイオム・バイオサイエンスの採用・求人情報ページです。株式会社カイオム・バイオサイエンス 私たちと一緒に ...See details»
4583:Tokyo 株価 - カイオム・バイオサイエンス - Bloomberg …
3 days ago カイオム・バイオサイエンス (4583:Tokyo) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。See details»
Anti-CDCP1 antibody conjugate - PBD - Chiome Bioscience
15 Jun 2023 Chiome Bioscience has filed patent application for Cells that produce human antibodies in Japan, US, Europe and China (Chiome Bioscience website, June 2023) You …See details»
お問い合わせ│株式会社カイオム・バイオサイエンス
An introduction to Chiome Bioscience’s antibody technology platform including our proprietary ADLib ® system. Pipeline パイプライン 当社が開発するパイプラインの進捗状況や詳細をご確 …See details»
Strategy 経営戦略 - 株式会社カイオム・バイオサイエンス
Chiome possesses antibody platforms including its proprietary technology, and extensive know-hows and experiences in protein/antibody engineering to streamline the process of drug …See details»
株式情報│株式会社カイオム・バイオサイエンス
An introduction to Chiome Bioscience’s antibody technology platform including our proprietary ADLib ® system. Pipeline パイプライン 当社が開発するパイプラインの進捗状況や詳細をご確 …See details»
決算短信│IRライブラリ│株式会社カイオム・バイオサイエンス
An introduction to Chiome Bioscience’s antibody technology platform including our proprietary ADLib ® system. Pipeline パイプライン 当社が開発するパイプラインの進捗状況や詳細をご確 …See details»